1Goldstein AJ,de Beurs E,Chambless DL,Wilson KA(2000)EMDR for panic disorder with agoraphobia:comparison with waiting list and credible attention-placebo control conditions.J Consuit Clin Psychol 68:947-956.
2Davidson JR, DuPont RL, Hedges D, Haskins JT (1999) Efficacy,safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalised anxiety disorder. J Clin Plychiatry 60: 528-535.
3Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum 8, Bell J,Maddock R, Hegel MT, Farfel G (2001a) Effcacy of sertraline in preventing relapse of posttrauma(ic stress disorder:results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 158:1974-1981.
4Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM(2001b) Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 58 485-492.
5Coldstein DJ,Sundell K(1999)A review of the safety of selective serotonin reuptake inhibitors during pregnancy.Hum Psychopharmacol Clin Exp 14:319-324.
7Goodman WK,Price LH,Rasmussen SA,Delgado PL,Heninger GR,Charney DS(1998b)Efficacy of fluvoxamine in obsessivecompulsive disorder.A double-blind comparison with placebo.Arch Cen Psychiatry 46:36-44.
8Goodman WK,Kozak MJ,Liebowitz M,White KL(1996)Treatment of obsessive-compulsive disorder with fluvoxamine:a muliticentre,double-blind,placebo-controlled trial.Int Clin Psychopharmacol 11:21-29.
9Gorman JM,Liebowitz MR,Fyer AJ,Goetz D,Campeas RB,Fyer MR,Davies SO,Klein DF(1987)An open trial of fluoxetine in the treatment of panic attacks[published erratum appears in J Clin Psychopharmacol 1988,8:13].J Clin Psychopharmacol 7:329-332.
10Eandelow, S. (2002) Epidemiology of Depression and Anxiety. In:Kasper S. et al. (eds.) Handbook on Depression and Anxiety. M.Dekker, New York (in press).
